QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NYSE:BHVN

Biohaven (BHVN) Stock Forecast, Price & News

$17.65
+0.41 (+2.38%)
(As of 09/26/2023 ET)
Compare
Today's Range
$17.17
▼
$18.15
50-Day Range
$16.93
▼
$25.52
52-Week Range
$5.54
▼
$26.64
Volume
849,717 shs
Average Volume
969,315 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Biohaven MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.1% Upside
$25.25 Price Target
Short Interest
Bearish
9.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2.90 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.99) to ($4.81) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

242nd out of 964 stocks

Pharmaceutical Preparations Industry

93rd out of 443 stocks

See Top Rated MarketRank™ Stocks Here

BHVN stock logo

About Biohaven (NYSE:BHVN) Stock

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Price History

BHVN Stock News Headlines

September 22, 2023 | finance.yahoo.com
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
September 19, 2023 | americanbankingnews.com
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Buy" from Brokerages
September 26, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 5, 2023 | markets.businessinsider.com
Biohaven Reports Positive Data From EEG Biomarker Study Of BHV-7000
September 5, 2023 | finance.yahoo.com
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
August 28, 2023 | seekingalpha.com
Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
August 16, 2023 | msn.com
JP Morgan Maintains Biohaven (BHVN) Overweight Recommendation
August 15, 2023 | fool.com
Biohaven (NYSE: BHVN)
September 26, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
August 9, 2023 | finance.yahoo.com
Independent Director of Biohaven Picks Up 1.8% More Stock
August 8, 2023 | benzinga.com
$2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
August 3, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
July 31, 2023 | finance.yahoo.com
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
July 31, 2023 | finance.yahoo.com
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
July 28, 2023 | markets.businessinsider.com
Biohaven Stock Is Plunging Today - Here's Why
July 28, 2023 | seekingalpha.com
Biohaven falls as FDA rejects filing for movement disorder therapy
July 28, 2023 | msn.com
Biohaven (NYSE:BHVN) Tanks on FDA Snub for Troriluzole in SCA
July 28, 2023 | finance.yahoo.com
Why Biohaven Stock Is Crashing Today
July 27, 2023 | finance.yahoo.com
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
July 17, 2023 | msn.com
Cantor Fitzgerald Reiterates Biohaven (BHVN) Overweight Recommendation
July 4, 2023 | finance.yahoo.com
BHVN - Biohaven Ltd.
June 15, 2023 | seekingalpha.com
Biohaven: A Promising Investment In Innovative Neurological Therapies
June 6, 2023 | seekingalpha.com
Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
June 6, 2023 | msn.com
BTIG Reiterates Biohaven (BHVN) Buy Recommendation
June 5, 2023 | markets.businessinsider.com
Biohaven Ltd. (BHVN) Gets a Buy from BTIG
June 1, 2023 | seekingalpha.com
Biohaven hits an all-time high after R&D Day
June 1, 2023 | finance.yahoo.com
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
7/31/2023
Today
9/26/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:BHVN
Previous Symbol
NASDAQ:BHVN
CUSIP
N/A
CIK
1689813
Web
www.biohavenpharma.com
Phone
203-404-0410
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.25
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+40.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($7.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-570,280,000.00
Net Margins
N/A
Pretax Margin
-255.54%
Return on Equity
-114.99%
Return on Assets
-89.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.94
Quick Ratio
4.94

Sales & Book Value

Annual Sales
$462.51 million
Price / Sales
2.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.90 per share
Price / Book
2.28

Miscellaneous

Outstanding Shares
68,320,000
Free Float
57,728,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.12
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Vladimir Coric M.D. (Age 52)
    Chairman & CEO
    Comp: $1.85M
  • Mr. Matthew Buten (Age 62)
    Chief Financial Officer
    Comp: $939.45k
  • Dr. Bruce D. Car DACVP (Age 61)
    Ph.D., Chief Scientific Officer
    Comp: $646.89k
  • Ms. Deb Young
    Director of Regulatory Affairs & Operations
  • Mr. George C. ClarkMr. George C. Clark (Age 39)
    VP & Chief Accounting Officer
  • Ms. Jennifer Porcelli
    VP of Investor Relations
  • Mr. Warren Volles J.D.
    Gen. Counsel & Chief Legal Officer
  • Mr. Clifford Bechtold M.S.
    Chief Compliance Officer
  • Ms. Kimberly GentileMs. Kimberly Gentile (Age 57)
    Sr. VP of Clinical Operations
  • Mr. John TiltonMr. John Tilton (Age 55)
    Chief Commercial Officer of Rare Diseases

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

What is Biohaven's stock price forecast for 2023?

6 equities research analysts have issued 12 month price targets for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $31.00. On average, they predict the company's share price to reach $25.25 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 on January 1st, 2023. Since then, BHVN shares have increased by 29.5% and is now trading at $17.98.
View the best growth stocks for 2023 here.

Are investors shorting Biohaven?

Biohaven saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 5,520,000 shares, an increase of 12.7% from the July 31st total of 4,900,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 4.9 days. Currently, 9.5% of the shares of the company are sold short.
View Biohaven's Short Interest.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BHVN earnings forecast.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.14.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven's stock symbol?

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.49%), Suvretta Capital Management LLC (5.66%), State Street Corp (4.20%), Holocene Advisors LP (3.02%), Geode Capital Management LLC (1.76%) and Point72 Asset Management L.P. (1.71%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Vlad Coric and William A Jones Jr.
View institutional ownership trends.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven's stock price today?

One share of BHVN stock can currently be purchased for approximately $17.98.

How much money does Biohaven make?

Biohaven (NYSE:BHVN) has a market capitalization of $1.23 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($7.42) on an earnings per share basis.

How many employees does Biohaven have?

The company employs 928 workers across the globe.

How can I contact Biohaven?

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -